Skip to main content
Premium Trial:

Request an Annual Quote

Researchers Demonstrate Feasibility of Whole-Genome Sequencing in the Clinic

Premium

Researchers at the Mayo Clinic in Scottsdale, Ariz., and at the nearby Translational Genomics Research Institute in Phoenix are moving clinicians one step closer to using whole-genome sequencing as a diagnostic tool. The team successfully sequenced tumor and normal cells from a male patient with pancreatic cancer, making him the first patient at the Mayo Clinic to undergo whole-genome sequencing. After comparing both sequences — which totaled more than 6 billion bases — clinicians and researchers were able to pinpoint genetic changes that were crucial in tailoring a more effective treatment plan for the patient. According to Mitesh Borad, an assistant professor at the Mayo Clinic, this study not only revealed useful discoveries that could make a difference in a single patient's recovery, it also demonstrated that whole-genome sequencing can be utilized in the clinic in a timely fashion.

"Our work demonstrates that turnaround can be achieved in a timeline that is conducive to point-of-care application of results — roughly six to eight weeks," Borad says. "Whole-genome sequencing had long been identified as a potential game-changer, but cost and time limitations had prevented its application in a comprehensive fashion," he adds. But even with clinicians' concerns over cost and turnaround time on the decline, regulatory hurdles — such as Clinical Laboratory Improvement Amendments considerations — remain. "Despite these concerns, utilization of this approach are clearly the way forward, and it is only a matter of time before whole- or targeted-genome sequencing becomes routine in the clinical sphere, ranging from primary care to specialty areas such as oncology." As part of this study, Borad and his colleagues also report their detection of several previously unrecognized polymorphisms in a number of proteins implicated in pathways amenable to therapeutic intervention.

In addition to the pancreatic case study, the Mayo Clinic-led team also used whole-genome sequencing on an acute myelogenous leukemia patient, in whom they found a novel mutation in IDH1. In their subsequent analysis of 187 additional samples, the team found 15 other AML cases with this mutation. "We have more demand for this sort of technology than available capacity, especially with regards to trained professionals in the sphere of genomic bio-informatics," Borad says. "Hopefully, the availability of next-generation bioinformatic tools will allow for this piece of the process to become largely automated in the future. Scaling up and streamlining to further reduce timelines and cost will be key priorities as well."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.